Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Retatrutide | Selegiline | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | — | — |
| Timing | — | — |
| Cycle Duration | — | — |
| Evidence Level | Emerging (Phase 3 ongoing) | Strong |
Triple incretin agonist (GIP/GLP-1/glucagon receptor). Combines appetite suppression and insulin sensitization of GLP-1 with the thermogenic and lipolytic effects of glucagon receptor activation. Produced the greatest weight loss of any anti-obesity agent in Phase 2 trials (~24% at 48 weeks).
Selective MAO-B inhibitor that raises dopaminergic tone at lower doses and is used clinically in Parkinson's disease and select mood protocols.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →